GlassScriptPhysician profile
Marco Ruella
NPI 1922562362
$26,866.42
in general payments reported to CMS, 2019-2025
16 companies · $9,590 in 2025
The $9,590 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $4,571 · 2021: $6,500 · 2022: $481 · 2023: $4,325 · 2024: $1,047 · 2025: $9,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,471.00 |
| Food and Beverage | $490.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,207.31 | 2020-2023 | |
| Glaxosmithkline, LLC. | $6,500.00 | 2021 | |
| Abbvie INC. | $4,400.07 | 2025 | |
| Astrazeneca Uk Limited | $2,375.00 | 2025 | |
| Tersera Therapeutics LLC | $966.00 | 2025 | Zoladex |
| Zoll Medical Corporation | $950.00 | 2024 | Defibrillator |
| Beigene USA, INC. | $950.00 | 2023 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $697.00 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $500.00 | 2025 | |
| Stryker Corporation | $433.00 | 2025 | |
| Gilead Sciences, INC. | $353.31 | 2019 | |
| Pfizer INC. | $143.64 | 2025 | |
| Kite Pharma, INC. | $124.87 | 2023 | Yescarta |
| Kyowa Kirin, INC. | $96.75 | 2024 | Poteligeo |
| Seagen INC. | $94.51 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Ruella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.